Motley Fool Wealth Management LLC Trims Holdings in DexCom, Inc. (NASDAQ:DXCM)

Motley Fool Wealth Management LLC reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 12.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 260,408 shares of the medical device company’s stock after selling 35,448 shares during the quarter. DexCom accounts for 1.0% of Motley Fool Wealth Management LLC’s investment portfolio, making the stock its 25th largest position. Motley Fool Wealth Management LLC owned 0.07% of DexCom worth $20,260,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in DXCM. Motley Fool Asset Management LLC lifted its stake in DexCom by 168.7% during the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock worth $17,993,000 after purchasing an additional 171,150 shares in the last quarter. Watts Gwilliam & Co. LLC acquired a new position in DexCom during the 4th quarter worth about $3,334,000. Congress Asset Management Co. boosted its holdings in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after acquiring an additional 1,332,522 shares during the period. Janney Montgomery Scott LLC boosted its holdings in DexCom by 2,226.6% during the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company’s stock valued at $18,085,000 after acquiring an additional 222,548 shares during the period. Finally, MayTech Global Investments LLC grew its position in DexCom by 53.6% in the 3rd quarter. MayTech Global Investments LLC now owns 259,257 shares of the medical device company’s stock valued at $17,381,000 after acquiring an additional 90,498 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares of the company’s stock, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 13,000 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares of the company’s stock, valued at $7,432,268.76. The trade was a 10.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 over the last quarter. Company insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on DXCM shares. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and increased their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Canaccord Genuity Group boosted their target price on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Trading Down 2.3 %

NASDAQ DXCM opened at $73.55 on Wednesday. The firm’s fifty day moving average price is $83.13 and its 200 day moving average price is $77.11. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company has a market capitalization of $28.74 billion, a price-to-earnings ratio of 51.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.